Blackstone Life Sciences committed up to $1.5 billion to support development of Pfizer’s ex-Metsera GLP-1 obesity candidate berobenatide. The co-funding arrangement is structured to provide additional resources for clinical-stage progression, reflecting investor focus on obesity therapeutics and pipeline scale-up.